Moderna Stock Dips More Than 20% Amid Slashed Sales Guidance

8月1日

Moderna Inc. (NASDAQ: MRNA) experienced a significant drop in its stock price, plummeting over 20%, following the announcement of reduced full-year sales guidance. The biotech company, renowned for its mRNA technology, reported second-quarter earnings that exceeded Wall Street expectations but highlighted several challenges that led to the downward revision of its revenue forecast.

Q2 Performance Overview
Moderna (MRNA) reported a narrower-than-expected loss of $3.33 per share, compared to analyst expectations of a $3.39 loss. The company's revenue for the second quarter stood at $241 million, surpassing the anticipated $132 million. However, this figure still represents a 30% year-over-year decline from the $344 million reported in the same period last year. The decrease was primarily driven by a 37% drop in product sales from its Covid-19 vaccine, Spikevax, which brought in $184 million during the quarter.

Slashed Full-Year Guidance
Despite the better-than-expected quarterly performance, Moderna (MRNA) reduced its 2024 product revenue guidance to a range of $3 billion to $3.5 billion, down from the previous forecast of $4 billion. The company attributed this adjustment to several factors:

1. Lower Sales in Europe: Moderna cited reduced demand for its Covid-19 vaccine in Europe as a major contributor to the lowered guidance.
2. Competitive U.S. Market: The company faces stiff competition in the U.S. market for respiratory vaccines, particularly for its newly approved respiratory syncytial virus (RSV) vaccine, mRESVIA. This vaccine, which targets older adults, entered a market already dominated by Pfizer and GSK.
3. Deferred International Revenue: Moderna indicated the potential for delayed international revenue, pushing some sales into 2025 due to ongoing budget constraints and economic pressures in various countries, including those exacerbated by the war in Ukraine.

Strategic Adjustments and Future Outlook
In response to these challenges, Moderna (MRNA) has been proactive in reducing operating costs. The company's cost of sales for Q2 was $115 million, down 84% from the same period last year. This reduction includes $14 million in write-downs of unused Covid-19 vaccine doses and $55 million in charges related to scaling back its manufacturing footprint.

CEO Stéphane Bancel emphasized the company's commitment to managing costs and optimizing its product pipeline. He noted, “We’ve been having quite intense discussions with governments across Europe to secure Covid vaccine supply contracts, but tight budgets and existing agreements with other suppliers have limited our opportunities.”

Despite the current setbacks, Moderna remains optimistic about its future. The company expects to return to sales growth in 2025 and aims to break even by 2026. Key to this strategy is the launch of new products and continued innovation within its pipeline. Moderna currently has 45 products in development, with five in late-stage trials. These include a combination shot targeting Covid-19 and the flu, which could receive approval as early as 2025, a stand-alone flu vaccine, and a personalized cancer vaccine in collaboration with Merck.

Investor Sentiment and Market Response
While Moderna's shares have risen nearly 20% this year due to increasing confidence in its pipeline and mRNA platform, the recent guidance cut has significantly impacted investor sentiment.

Modern stock (MRNA) has dropped from its consolidation zone and has formed a significant downward gap. In trading, gapping happens when the price of a security jumps to a new price that's not right next to the previous price, creating a gap on the price chart. This can occur during a trading day or when the markets are closed. Gaps can happen unexpectedly when the perceived value of an investment changes due to fundamental or technical factors, such as earnings. In this case, MRNA is in a downward gap, also known as a negative gap, which occurs when the opening price of a stock on the second day is lower than the closing price on the first day.

Conclusion
Moderna's recent financial performance highlights the volatility and competitive nature of the biotech industry, particularly in the evolving landscape of respiratory vaccines. While the company faces immediate challenges, its strategic cost management and robust pipeline position it for potential recovery and growth in the coming years.